Document Detail

Valproate-induced hyperammonemic encephalopathy.
MedLine Citation:
PMID:  16774619     Owner:  NLM     Status:  MEDLINE    
Valproate-induced hyperammonemic encephalopathy (VHE) is an unusual complication characterized by a decreasing level of consciousness, focal neurological deficits, cognitive slowing, vomiting, drowsiness, and lethargy. We have thoroughly reviewed the predisposing factors and their screening, the biochemical and physiopathological mechanisms involved, the different treatments described, and those that are being investigated. Etiopathogenesis is not completely understood, although hyperammonemia has been postulated as the main cause of the clinical syndrome. The increase in serum ammonium level is due to several mechanisms, the most important one appearing to be the inhibition of carbamoylphosphate synthetase-I, the enzyme that begins the urea cycle. Polytherapy with several drugs, such as phenobarbital and topiramate, seems to contribute to hyperammonemia. Hyperammonemia leads to an increase in the glutamine level in the brain, which produces astrocyte swelling and cerebral edema. There are several studies that suggest that treatment with supplements of carnitine can lead to an early favorable clinical response due to the probable carnitine deficiency induced by a valproate (VPA) treatment. Development of the progressive confusional syndrome, associated with an increase in seizure frequency after VPA treatment onset, obliges us to rule out VHE by screening for blood ammonium levels and the existence of urea cycle enzyme deficiency, such as ornithine carbamoyltransferase deficiency. Electroencephalography (EEG) is characterized by signs of severe encephalopathy with continuous generalized slowing, a predominance of theta and delta activity, occasional bursts of frontal intermittent rhythmic delta activity, and triphasic waves. These EEG findings, as well as clinical manifestations and hyperammonemia, tend to normalize after VPA withdrawal.
N Segura-Bruna; A Rodriguez-Campello; V Puente; J Roquer
Related Documents :
24809929 - Differences in breast-feeding initiation and continuation by maternal diabetes status.
23826679 - Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis.
24988689 - Metabolic syndrome and diabetes mellitus in childhood cancer survivors.
1431769 - Body mass and weight as indicators for cholesterol screening.
25030559 - Status of diabetes treatment in japanese adults: an analysis of the 2009 japan society ...
7148899 - Comparison of glycohemoglobin determination and the one-hour oral glucose screen in the...
15787899 - A randomized trial of regular standardized telephone contact by a diabetes nurse educat...
1615889 - Liver and gallbladder disease before and after very-low-calorie diets.
17583179 - A review of picotamide in the reduction of cardiovascular events in diabetic patients.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Acta neurologica Scandinavica     Volume:  114     ISSN:  0001-6314     ISO Abbreviation:  Acta Neurol. Scand.     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-06-15     Completed Date:  2006-09-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370336     Medline TA:  Acta Neurol Scand     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  1-7     Citation Subset:  IM    
Servei de Neurologia, Hospital del Mar, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticonvulsants / adverse effects*
Brain / metabolism,  physiopathology
Brain Edema / chemically induced,  metabolism,  physiopathology
Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing) / antagonists & inhibitors,  metabolism
Carnitine / therapeutic use
Diagnosis, Differential
Glutamic Acid / metabolism*
Glutamine / metabolism
Hepatic Encephalopathy / chemically induced*,  diagnosis,  physiopathology
Hyperammonemia / chemically induced*,  metabolism,  physiopathology
Valproic Acid / adverse effects*
Reg. No./Substance:
0/Anticonvulsants; 541-15-1/Carnitine; 56-85-9/Glutamine; 56-86-0/Glutamic Acid; 99-66-1/Valproic Acid; EC Synthase (Glutamine-Hydrolyzing)

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Closing the loop: combining insulin pumps and glucose sensors in children with type 1 diabetes melli...
Next Document:  The epidemiology of post-stroke epilepsy according to stroke subtypes.